Understanding PI3K inhibitor mechanism of action

被引：2
|
作者：
Sarah Crunkhorn
机构：
来源：
Nature Reviews Drug Discovery | 2021年 / 20卷 / 11期
关键词：
D O I：
10.1038/d41573-021-00173-w
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：816 / 816
相关论文
共 50 条
  • [31] Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
    Kumar, Anshul
    Bhatia, Rohit
    Chawla, Pooja
    Anghore, Durgadas
    Saini, Vipin
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (10) : 1158 - 1172
  • [32] The PI3K inhibitor arsenal: choose your weapon!
    Crabbe, Tom
    Welham, Melanie J.
    Ward, Stephen G.
    TRENDS IN BIOCHEMICAL SCIENCES, 2007, 32 (10) : 450 - 456
  • [33] PI3K Inhibitor for Lymphoma Withdrawn from the Market
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2022, 122 (10) : 20 - 20
  • [34] Game of isoforms: PI3K β-sparing inhibitor is coming
    Cheng, Hanyin
    Aplin, Andrew E.
    PIGMENT CELL & MELANOMA RESEARCH, 2015, 28 (02) : 133 - 134
  • [35] First-in-class PI3K inhibitor advances
    Nature Reviews Drug Discovery, 2013, 12 : 817 - 817
  • [36] Duvelisib, a New PI3K Inhibitor for Lymphoid Malignancies
    Lamanna, Nicole
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (10) : 606 - 608
  • [37] A novel natural product inhibitor for the PI3K pathway
    de Pedro, Nuria
    Cautain, Bastien
    Gonzalez-Menendez, Victor
    Crespo, Gloria
    Rodriguez, Lorena
    Diaz, Caridad
    Fernandez-Acero, Teresa
    Cid, Victor J.
    Molina, Maria
    Reyes, Fernando
    Vicente, Francisca
    Genilloud, Olga
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Development and evaluation of a novel MAPK and PI3K inhibitor
    Galban, S.
    Van Dort, M.
    Hao, H.
    Espinoza, C.
    Heist, K.
    Nino, C.
    Galban, C.
    Besirli, C.
    Ross, B.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S33 - S34
  • [39] Development of an HDAC/PI3K dual inhibitor in academia
    Saijo, Ken
    Ishioka, Chikashi
    ANNALS OF ONCOLOGY, 2017, 28 : 49 - 49
  • [40] PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
    Greenwell, I. Brian
    Ip, Andrew
    Cohen, Jonathon B.
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 821 - 828
12345